PMID- 26536425
OWN - NLM
STAT- MEDLINE
DCOM- 20160314
LR  - 20181202
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 20
IP  - 6
DP  - 2015 Dec
TI  - Intravenous immunoglobulin in kidney transplantation.
PG  - 630-7
LID - 10.1097/MOT.0000000000000250 [doi]
AB  - PURPOSE OF REVIEW: Antibody-mediated injury of renal allografts has assumed 
      increasing importance with the availability of potent immunosuppressants directed 
      against T-lymphocytes. Intravenous immunoglobulin (IVIG) has been used for 
      prevention and treatment of antibody-mediated rejection. The review summarizes 
      recent advances that shed light on mechanisms of action of IVIG and outlines 
      current roles of IVIG in kidney transplantation. RECENT FINDINGS: Observational 
      studies support the use of IVIG for desensitization and treatment of acute 
      rejection. Most studies are small and uncontrolled, but a matched case-control 
      study reported a better survival with incompatible live-donor kidney transplant 
      after desensitization using IVIG-containing regimens compared with dialysis or 
      waiting for compatible transplant. Recent data indicate that variations in 
      glycosylation and amino acid sequence cause the crystallizable fragment of 
      immunoglobulin G to assume specific conformations that have high affinity for 
      canonical crystallizable fragment receptors (FcR) or a newly discovered class of 
      FcRs, labelled type II FcRs. Signaling through type II FcRs appears to trigger 
      anti-inflammatory pathways. SUMMARY: Recent discoveries expand our understanding 
      of the mechanism of action of IVIG. Future research is expected to clarify the 
      relevance of these findings to humans and could lead to the development of novel 
      immunomodulatory agents.
FAU - Tedla, Fasika M
AU  - Tedla FM
AD  - Division of Nephrology, Department of Medicine, SUNY Downstate Medical Center, 
      Brooklyn, New York, USA.
FAU - Roche-Recinos, Andrea
AU  - Roche-Recinos A
FAU - Brar, Amarpali
AU  - Brar A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/immunology
MH  - Graft Rejection/prevention & control
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunosuppressive Agents/therapeutic use
MH  - *Kidney Transplantation
MH  - T-Lymphocytes/immunology
EDAT- 2015/11/05 06:00
MHDA- 2016/03/15 06:00
CRDT- 2015/11/05 06:00
PHST- 2015/11/05 06:00 [entrez]
PHST- 2015/11/05 06:00 [pubmed]
PHST- 2016/03/15 06:00 [medline]
AID - 00075200-201512000-00009 [pii]
AID - 10.1097/MOT.0000000000000250 [doi]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2015 Dec;20(6):630-7. doi: 
      10.1097/MOT.0000000000000250.